Emerging evidence on the pathobiology of mucositis
详细信息 查看全文
- 作者：Noor Al-Dasooqi (1)
Stephen T. Sonis (2)
Joanne M. Bowen (3)
Emma Bateman (1)
Nicole Blijlevens (4)
Rachel J. Gibson (5)
Richard M. Logan (6)
Raj G. Nair (7)
Andrea M. Stringer (8)
Roger Yazbeck (8)
Sharon Elad (9)
Rajesh V. Lalla (10) - 关键词：Mucosal injury ; Cancer therapy ; Targeted drugs ; Toxicity ; Alimentary tract ; Pharmacogenetics
- 刊名：Supportive Care in Cancer
- 出版年：2013
- 出版时间：July 2013
- 年：2013
- 卷：21
- 期：7
- 页码：2075-2083
- 全文大小：180KB
- 参考文献：1. Elting L et al (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531鈥?539 CrossRef
2. Sonis S et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995鈥?025 CrossRef
3. Capp A et al (2009) Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol 90:400鈥?07 CrossRef
4. Keefe D et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820鈥?31 CrossRef
5. Aprile G et al (2008) Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 112:284鈥?92 CrossRef
6. Murphy B (2007) Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5:13鈥?1
7. Sonis S (2004) The pathobiology of mucositis. Nat Rev Cancer 4:277鈥?84 CrossRef
8. Sonis S et al (2002) The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif 35:s92鈥搒102 CrossRef
9. Sonis S et al (1990) An animal model for mucositis induced by cancer chemotherapy. Oral Surg, Oral Med, Oral Pathol 69:437鈥?43 CrossRef
10. Paris F et al (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293鈥?97 CrossRef
11. Logan R et al (2009) Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63:239鈥?51 CrossRef
12. Sonis S et al (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373鈥?81 CrossRef
13. Yeoh A et al (2005) Nuclear factor 魏B (NF魏B) and cyclooxygenase-2 (COX-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 63:1295鈥?303 CrossRef
14. Manzano M et al (2007) Intestinal toxicity induced by 5-fluorouracil in pigs: a new preclinical model. Chemotherapy 53:344鈥?55 CrossRef
15. Stringer A et al (2009) Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 90:489鈥?99 CrossRef
16. Stringer A et al (2009) Chemotherapy-induced changes to microflora: evidence and implications of change. Curr Drug Metab 10:79鈥?3 CrossRef
17. Stringer A et al (2007) Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med 232:96鈥?06
18. Al-Dasooqi N et al (2011) Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. Int J Exp Pathol 92:357鈥?65 CrossRef
19. Al-Dasooqi N et al (2010) Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the DA rat. Exp Biol Med 235:1244鈥?256 m.2010.010082">CrossRef
20. Anthony L et al (2007) New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer 14:516鈥?18 CrossRef
21. Hannum Y (1997) Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845鈥?853
22. Kerr J, Winterford C, Harmon B (1994) Apoptosis: its significant in cancer and cancer therapy. Cancer 73:2013鈥?026 CrossRef
23. Gibson R et al (2005) Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med 4:188鈥?95 CrossRef
24. Bowen J et al (2005) Cytotoxic chemotherapy up-regulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37:56鈥?2 CrossRef
25. Keefe D (2000) Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47:632鈥?37 CrossRef
26. Sonis S et al (1992) Effect of epidermal gorwth factor on ulcerative mucositis in hamsters that receive chemotherapy. Oral Surg, Oral Med, Oral Pathol 74:749鈥?55 CrossRef
27. Gibson R et al (2007) Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 53:360鈥?69 CrossRef
28. Gibson R et al (2006) Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. Asia Pac J Clin Oncol 2:39鈥?9 CrossRef
29. Li C et al (2011) The correlation between the severity of radiotherapy-induced glossitis and endothelial cell injury in local tissues in a rat model. Med Oral Pathol Oral Cir Bucal 16:e711鈥揺715 medoral.17057">CrossRef
30. Carneiro-Filho B et al (2004) Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig Dis Sci 49:65鈥?2 CrossRef
31. Chen P et al (2011) Role of AMP-18 in oral mucositis. Oral Oncol 47:831鈥?39 CrossRef
32. Huang T et al (2009) Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. Biochem Biophys Res Commun 389:634鈥?39 CrossRef
33. Meredith J, Fazeli B, Schwartz M (1993) The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953鈥?61
34. Afshar S, Phelan K, O'Donnell C, Bragdon C, Castro D, Sonis S (2002) A new in vivo model for the study of mucosal disease. International Association for Dental Research Meeting Abstract 16220
35. Phelan S, Afshar S, O'Donnell C, Bragdon C, Castro D, Shklar G, Sonis S (2002) A mucosal graft model to evaluate radiation induced injury. International Association for Dental Research Meeting Abstract 0221
36. Beutheu Youmba S et al (2012) Methotrexate modulates tight junctions through NFkB, MEK, and JNK pathways. J Pediatric Gastroenterol Nutr 54:463鈥?70 CrossRef
37. Hamada K et al (2010) Zonula Occluden-1 alterations and enhances intestinal permeability in methotrexate-treated rats. Cancer Chemother Pharmacol 66:1031鈥?038 CrossRef
38. Al-Sadi R et al (2010) IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway. Am J Pathol 177:2310鈥?322 CrossRef
39. Al-Sadi R et al (2008) Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J Immunol 180:5653鈥?661
40. Ma T et al (2004) TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 286:G367鈥揋376 CrossRef
41. Han X, Fink M, Delude R (2003) Proinflammatory cytokines cause NO*-dependent and -independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock 19:229鈥?37 CrossRef
42. Melichar B et al (2005) Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy 51:336鈥?38 CrossRef
43. Logan R et al (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 62:33鈥?1 CrossRef
44. Sonis S (2002) The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral BiolMed 13:380鈥?89 CrossRef
45. Sonis S (2004) A biological approach to mucositis. J Support Oncol 2:21鈥?2
46. Sonis S et al (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170鈥?76 CrossRef
47. Logan R et al (2007) Nuclear factor-kB (NFkB) and cyclooxygenase-2 expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43:395鈥?01 CrossRef
48. Haagen J et al (2009) Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. Radiother Oncol 92:472鈥?76 CrossRef
49. Ong Z et al (2010) Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 16:22 CrossRef
50. Logan R et al (2007) The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33:448鈥?60 CrossRef
51. Logan R et al (2008) Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 7:1139鈥?145 CrossRef
52. Lima V et al (2005) Effects of tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. Eur J Oral Sci 113:210鈥?17 CrossRef
53. Melo M et al (2008) Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 61:775鈥?84 CrossRef
54. Fiochhi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182鈥?05 CrossRef
55. de Koning B et al (2006) Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol 18:941鈥?49 mm/dxl030">CrossRef
56. Bultzingslowen I et al (2006) Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer 14:519鈥?27 CrossRef
57. Gibson R et al (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751鈥?757 CrossRef
58. Antin J et al (2002) A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 29:373鈥?77 mt.1703394">CrossRef
59. Zhao J et al (2004) Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 10:2851鈥?859 CrossRef
60. Frei E et al (1965) The nature and control of infections in patients with acute leukemia. Cancer Res 25:1511鈥?515
61. Dreizen S, Bodey G, Brown L (1974) Opportunistic gram-negative bacillary infections in leukemia. Oral manifestations during myelosuppression. Post Med 55:133鈥?39
62. Stringer A et al (2008) Faecal microflora and 尾-glucuronidase expression are altered in an irinotecan-induced diarrhoea model in rats. Cancer Biol Ther 7:1919鈥?925 CrossRef
63. Stringer A et al (2009) Gastrointestinal microflora and mucins play a role in the development of 5-fluorouracil-induced gastrointestinal mucositis in rats. Exp Biol Med 234:430鈥?41 CrossRef
64. Shao Z et al (2011) Effects of intensity-modulated radiotherapy on human oral microflora. J Radiat Res 52:834鈥?39 CrossRef
65. Napenas J et al (2010) Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endodentics 109:554鈥?60 CrossRef
66. van Vliet M et al. (2010) The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis / . PLoS Pathog 6(5): e1000879
67. Martin M, van Saene H (1992) The role of oral microorganisms in cancer therapy. Curr Opin Dent 2:81鈥?4
68. Bochud P et al (1994) Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 18:25鈥?1 CrossRef
69. Ruescher T et al (1998) The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82:2275鈥?281 CrossRef
70. Soga Y et al (2011) Bacterial substitution of coagulase-negative staphylococci for streptococci on the oral mucosa after hematopoietic cell transplantation. Support Care Cancer 19:995鈥?000 CrossRef
71. van der Velden W, Donnelly J, Blijlevens N (2012) Lymphocyte subsets, granulocyte-colony-stimulating factor responsiveness and post-stem cell transplantation infections: mucositis is the underestimated confounder? Cytotherapy 14:381鈥?83 CrossRef
72. Sonis S (2009) Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45:1015鈥?020 CrossRef
73. Barasch A et al (2006) Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer 14:528鈥?32 CrossRef
74. Blijlevens N, Donnelly J, DePauw B (2000) Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 25:1269鈥?278 mt.1702447">CrossRef
75. Prisciandaro L et al (2011) Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol Ther 11:671鈥?77 CrossRef
76. Gibson R et al. (2013) Systematic review of agents for the management of gastrointestinal mucositis in cancer patients / . Supportive Care Cancer 21(1):313-26
77. Blijlevens N, Donnelly J (2011) Mucosal barrier injury and infections. In: Safdar A (ed) Principles and practice of cancer infectious diseases, current clinical oncology. Springer Science, New York
78. Wisplinghoff H et al (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103鈥?110 CrossRef
79. Keefe D, Bateman E (2011) Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 9:98鈥?09 CrossRef
80. Sonis S et al (2010) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116:210鈥?15
81. Toi M et al (2009) Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101(10):1676鈥?682 CrossRef
82. Sawaki M et al (2004) Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori 90(1):40鈥?3
83. Keefe D, Gibson R (2007) Mucosal injury from targeted anticancer therapy. Support Care Cancer 15:483鈥?90 CrossRef
84. Burris H (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9:10鈥?5 CrossRef
85. Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733鈥?743 CrossRef
86. Al-Dasooqi N et al (2008) Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Investig New Drugs 27:173鈥?78 CrossRef
87. Fountzilas G et al (2001) Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 12:1545鈥?551 CrossRef
88. Bartsch R et al (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25:3853鈥?858 CrossRef
89. Ruiz M et al (2008) Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28聽days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 62:1085鈥?090 CrossRef
90. Bowen J et al (2012) Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhoea. Cancer Biol Ther 13(13):1269-75
91. Peterson D, Keefe D, Sonis S (2012) New frontiers in mucositis. ASCO Educational Book. American Society of Clinical Oncology, Alexandria, pp. 545鈥?1
92. Keefe D (1998) The effect of cytotoxic chemotherapy on the mucosa of the small intestine. Department of Medicine University of Adelaide, Adelaide
93. Pico J, Avila-Garavito A, Naccache P (1998) Mucositis: its occurence, consequences and treatment in the oncology setting. The Oncologist volume 3:p446鈥?51
94. Sloan J et al (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20:1491鈥?498 CrossRef
95. Pratesi N et al (2011) Association between single nucleotide polymorphisms in XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol 99:356鈥?62 CrossRef
96. West C, Dunning A, Rosenstein (2012) Genome-wide association studies and prediction of normal tissue toxicity. Sem Radiat Oncol 22:91鈥?9 mradonc.2011.12.007">CrossRef
97. Thomas F et al (2011) Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer 105:1654鈥?662 CrossRef
98. Werbrouck J et al (2009) Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys 73:1187鈥?195 CrossRef
99. Schwab M et al (2008) Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26:2131鈥?138 CrossRef
100. Cho H et al (2010) Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer CGenet Cytogenet 198:40鈥?6 CrossRef
101. Hahn T et al (2010) A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol Blood Marrow Transplant 16:801鈥?08 mt.2010.01.001">CrossRef
102. Alterovitz G et al (2011) Personalized medicine for mucositis: bayesian networks identify unique gene clusters which predict the response to gamma-D-glutamyl-L-tryptophan (SCV-07) for the attenuation of chemoradiation-induced oral mucositis. Oral Oncol 47:951鈥?55 CrossRef
103. Roseth A (2003) Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis 35:607鈥?09 CrossRef
104. Lutgens L et al. (2005) Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests / . Cancer 103(1):191鈥?
105. Xanthinaki A et al (2008) Apoptosis and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer 16:1025鈥?033 CrossRef - 作者单位：Noor Al-Dasooqi (1)
Stephen T. Sonis (2)
Joanne M. Bowen (3)
Emma Bateman (1)
Nicole Blijlevens (4)
Rachel J. Gibson (5)
Richard M. Logan (6)
Raj G. Nair (7)
Andrea M. Stringer (8)
Roger Yazbeck (8)
Sharon Elad (9)
Rajesh V. Lalla (10)
1. Discipline of Medicine, University of Adelaide, North Terrace, Adelaide, SA, 5000, USA
2. Brigham and Women鈥檚 Hospital, Dana-Farber Cancer Institute, 75 Francis Street, Boston, MA, 02115, USA
3. Discipline of Physiology, University of Adelaide, North Terrace, Adelaide, SA, 5000, USA
4. Department of Haematology, University Medical Center Nijmegen, 6500HB, Nijmegen, The Netherlands
5. Discipline of Anatomy and Pathology, University of Adelaide, North Terrace, Adelaide, SA, 5000, USA
6. School of Dentistry, University of Adelaide, North Terrace, Adelaide, SA, 5005, USA
7. Discipline of Oral Medicine, Griffith University and Department of Haematology and Oncology, Queensland Health, Gold Coast, QLD, Australia
8. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia
9. Division of Oral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA
10. Section of Oral Medicine and Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington Avenue, Farmington, CT, 06030, USA - ISSN：1433-7339
文摘
Background Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely. Methods Panel members reviewed the biomedical literature on mucositis pathobiology published between January 2005 and December 2011. Results Recent research has provided data on the contribution of tissue structure changes, inflammation and microbiome changes to the development of mucositis. Additional research has focused on targeted therapy-induced toxicity, toxicity clustering and the investigation of genetic polymorphisms in toxicity prediction. This review paper summarizes the recent evidence on these aspects of mucositis pathobiology. Conclusion The ultimate goal of mucositis researchers is to identify the most appropriate targets for therapeutic interventions and to be able to predict toxicity risk and personalize interventions to genetically suitable patients. Continuing research efforts are needed to further our understanding of mucositis pathobiology and the pharmacogenomics of toxicity.